NORAD and breast cancer: When we split breast cancer patients into subtypes and evaluated the expression levels of each lncRNA, we could observe that a higher expression of NORAD was found in luminal subtypes, usually lower-risk patients, in comparison to basal-like, which have a higher risk of relapse.